search
Back to results

DENEX Renal Denervation in Patients With Uncontrolled Hypertension: Safety Study

Primary Purpose

Uncontrolled Hypertension

Status
Completed
Phase
Not Applicable
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Renal denervation
Sponsored by
Kalos Medical
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Uncontrolled Hypertension focused on measuring Uncontrolled Hypertension, Renal Denervation

Eligibility Criteria

20 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Individual is ≥ 20 years of age at time of consent
  2. Individual has office systolic blood pressure (SBP) of ≥ 150 mmHg
  3. Individual has daytime 24-hour Ambulatory Blood Pressure Monitoring (ABPM) SBP of ≥ 140 mmHg
  4. Individual maintains the following 3 antihypertensive medications: thiazide-type diuretic, calcium-channel blocker, and angiotensin-converting enzyme inhibitor or angiotensin receptor blocker (for at least 6 weeks before the screening visit) that is expected to be maintained without changes for at least 6 months.

Exclusion Criteria:

  1. Main renal artery contains renal artery stenosis >50%
  2. Individual has confirmed anatomical findings in kidneys or renal arteries through CT scan or angiogram
  3. Undergone prior renal angioplasty
  4. Main renal arterial vessel for each kidney <4 and >8 mm in diameter, or <20 mm length
  5. Individual has an Estimated glomerular filtration rate <45 mL/min/1.73 m2 at screening visit
  6. Individual has experienced myocardial infarction, unstable angina pectoris, syncope, or a cerebrovascular accident within 3 months of the screening period, or has widespread atherosclerosis, with documented intravascular thrombosis or unstable plaques
  7. Individual has Hemodynamically or echocardiography significant valvular heart disease
  8. Individual has secondary hypertension (pheochromocytoma, Cushing syndrome,coarctation of the aorta, renovascular hypertension, primary hyperaldosteronism, or other secondary hypertension)
  9. Individual has documented primary pulmonary hypertension
  10. Individual has orthostatic hypotension with symptom
  11. Individual requires chronic oxygen support for sleep apnea
  12. Individual is taking chronic NSAIDs (Non-Steroidal Anti-Inflammatory Drugs). Only, Aspirin is permitted for cardiovascular disease prevention
  13. Individual has Type 1 diabetes mellitus

Sites / Locations

  • Pusan National University Hospital
  • Severance Hospital
  • Korea University Guro Hospital
  • Seoul St.Mary's Hospital
  • Uijeongbu St. Mary's Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Renal denervation therapy group

Arm Description

The subject treated by renal denervation by using DENEX system.

Outcomes

Primary Outcome Measures

Rate of all adverse events
rate of major adverse events for 1 month after the treatment

Secondary Outcome Measures

Ambulatory SBP change at 3,6,12,24 months
Change in systolic blood pressure as measured by 24-hour ABPM at 3, 6, 12, 24 months post denervation
Office SBP change at 1, 3, 6, 12, 18, 24 months
Change in office systolic blood pressure at 1, 3, 6, 12, 18, 24 months post denervation
Percentage of decreased office SBP >10, 15, 20 mmHg
Percentage of subjects decreased office systolic blood pressure > 10 mmHg, 15 mmHg, 20 mmHg at 1, 3, 6, 12, 18, 24 months post denervation

Full Information

First Posted
January 28, 2020
Last Updated
June 19, 2022
Sponsor
Kalos Medical
search

1. Study Identification

Unique Protocol Identification Number
NCT04248530
Brief Title
DENEX Renal Denervation in Patients With Uncontrolled Hypertension: Safety Study
Official Title
An Open-Label, Single Arm, Multicenter Feasibility Study to Evaluate the Safety of Catheter-Based Renal Denervation With the DENEX System in Patients With Uncontrolled Hypertension on Standard Medical Therapy
Study Type
Interventional

2. Study Status

Record Verification Date
May 2020
Overall Recruitment Status
Completed
Study Start Date
November 30, 2016 (Actual)
Primary Completion Date
July 1, 2019 (Actual)
Study Completion Date
May 7, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Kalos Medical

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
The study is the multicenter pilot study to obtain an assessment of the safety of renal denervation in the patients with uncontrolled hypertension on standard medical therapy in Korea.
Detailed Description
DENEX system developed by Handok Kalos Medical Inc. is a renal nerve blocking system to efficiently block the sympathetic nerve of the kidney with minimal invasive procedure. It was developed to block the sympathetic nerves distributed in blood vessel wall by delivering high frequency energy to the renal artery for the purpose of treating hypertension.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Uncontrolled Hypertension
Keywords
Uncontrolled Hypertension, Renal Denervation

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
16 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Renal denervation therapy group
Arm Type
Experimental
Arm Description
The subject treated by renal denervation by using DENEX system.
Intervention Type
Device
Intervention Name(s)
Renal denervation
Intervention Description
DENEX catheter is a device to treat resistant hypertension which delivers high-frequency energy through the three electrodes connected to the catheter in order to cauterize sympathetic nerve bundle.
Primary Outcome Measure Information:
Title
Rate of all adverse events
Description
rate of major adverse events for 1 month after the treatment
Time Frame
From baseline to 1 month post-procedure
Secondary Outcome Measure Information:
Title
Ambulatory SBP change at 3,6,12,24 months
Description
Change in systolic blood pressure as measured by 24-hour ABPM at 3, 6, 12, 24 months post denervation
Time Frame
From baseline to 3, 6, 12, 24 months post-procedure
Title
Office SBP change at 1, 3, 6, 12, 18, 24 months
Description
Change in office systolic blood pressure at 1, 3, 6, 12, 18, 24 months post denervation
Time Frame
From baseline to 1, 3, 6, 12, 18, 24 months post-procedure
Title
Percentage of decreased office SBP >10, 15, 20 mmHg
Description
Percentage of subjects decreased office systolic blood pressure > 10 mmHg, 15 mmHg, 20 mmHg at 1, 3, 6, 12, 18, 24 months post denervation
Time Frame
From baseline to 1, 3, 6, 12, 18, 24 months post-procedure

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Individual is ≥ 20 years of age at time of consent Individual has office systolic blood pressure (SBP) of ≥ 150 mmHg Individual has daytime 24-hour Ambulatory Blood Pressure Monitoring (ABPM) SBP of ≥ 140 mmHg Individual maintains the following 3 antihypertensive medications: thiazide-type diuretic, calcium-channel blocker, and angiotensin-converting enzyme inhibitor or angiotensin receptor blocker (for at least 6 weeks before the screening visit) that is expected to be maintained without changes for at least 6 months. Exclusion Criteria: Main renal artery contains renal artery stenosis >50% Individual has confirmed anatomical findings in kidneys or renal arteries through CT scan or angiogram Undergone prior renal angioplasty Main renal arterial vessel for each kidney <4 and >8 mm in diameter, or <20 mm length Individual has an Estimated glomerular filtration rate <45 mL/min/1.73 m2 at screening visit Individual has experienced myocardial infarction, unstable angina pectoris, syncope, or a cerebrovascular accident within 3 months of the screening period, or has widespread atherosclerosis, with documented intravascular thrombosis or unstable plaques Individual has Hemodynamically or echocardiography significant valvular heart disease Individual has secondary hypertension (pheochromocytoma, Cushing syndrome,coarctation of the aorta, renovascular hypertension, primary hyperaldosteronism, or other secondary hypertension) Individual has documented primary pulmonary hypertension Individual has orthostatic hypotension with symptom Individual requires chronic oxygen support for sleep apnea Individual is taking chronic NSAIDs (Non-Steroidal Anti-Inflammatory Drugs). Only, Aspirin is permitted for cardiovascular disease prevention Individual has Type 1 diabetes mellitus
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yangsu Jang
Organizational Affiliation
Division of Cardiology, Severance Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Pusan National University Hospital
City
Pusan
Country
Korea, Republic of
Facility Name
Severance Hospital
City
Seoul
ZIP/Postal Code
03722
Country
Korea, Republic of
Facility Name
Korea University Guro Hospital
City
Seoul
Country
Korea, Republic of
Facility Name
Seoul St.Mary's Hospital
City
Seoul
Country
Korea, Republic of
Facility Name
Uijeongbu St. Mary's Hospital
City
Uijeongbu
Country
Korea, Republic of

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
33377328
Citation
Kim CJ, Chang K, Kim BK, Park CG, Jang Y. An Open-label, Single-arm, Multicenter Feasibility Study Evaluating the Safety of Catheter-based Renal Denervation with DENEX in Patients with Uncontrolled Hypertension on Standard Medical Therapy. Korean Circ J. 2021 Jan;51(1):43-55. doi: 10.4070/kcj.2020.0391.
Results Reference
derived

Learn more about this trial

DENEX Renal Denervation in Patients With Uncontrolled Hypertension: Safety Study

We'll reach out to this number within 24 hrs